Proton therapy for Hodgkin lymphoma
- 386 Downloads
Hodgkin lymphoma has gone from an incurable disease to one for which the majority of patients will be cured. Combined chemotherapy and radiotherapy achieves the best disease control rates and results in many long-term survivors. As a result, a majority of long-term Hodgkin lymphoma survivors live to experience severe late treatment-related complications, especially cardiovascular disease and second malignancies. The focus of research and treatment for Hodgkin lymphoma is to maintain the current high rates of disease control while reducing treatment-related morbidity and mortality. Efforts to reduce late treatment complications focus on improvements in both systemic therapies and radiotherapy. Herein we review the basis for the benefits of proton therapy over conventional X-ray therapy. We review outcomes of Hodgkin lymphoma treated with proton therapy, and discuss the ability of protons to reduce radiation dose to organs at risk and the impact on the most significant late complications related to the treatment.
KeywordsProton therapy Hodgkin lymphoma Outcomes Cardiac Cancer Toxicity Radiotherapy Radiation Particle therapy
Compliance with Ethics Guidelines
Conflict of Interest
Dr. Michael S. Rutenberg and Dr. Stella Flampouri each declare no potential conflicts of interest.
Dr. Bradford S. Hoppe is a volunteer board member for the Proton Collaborative Group. Dr. Hoppe received payment for development of educational presentations including service on speakers' bureaus and travel/accommodations expenses covered or reimbursed by Procure for a lecture on the use of proton therapy in Hodgkin lymphoma and lung cancer.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest,published recently, have been highlighted as: • Of importance
- 2.Peters MV. A study of survivals in Hodgkin's disease treated radiologically. Am J Roentgenol Radium Ther. 1950;63:299–311.Google Scholar
- 7.Paganetti H. Late Effects from Scattered and Secondary Radiation. In: Pagnetti H, ed(s). Proton Therapy Physics. Boston: Massachusetts General Hospital and Harvard Medical School 2011, 555–70.Google Scholar
- 12.Hoppe BS, Flampouri S, Zaiden R, Slayton W, Sandler E, Ozdemir S, et al.. Involved-Node Proton Therapy in Combined-Modality Therapy for Hodgkin Lymphoma: Results of a Phase II Study. Int J Radiat Oncol Biol Phys. 2014;in press.Google Scholar
- 14.Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199–206.PubMedCrossRefGoogle Scholar
- 27.Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys. 2006;64:218–26.PubMedCrossRefGoogle Scholar
- 29.•Hoppe BS, Flampouri S, Su Z, Morris CG, Latif N, Dang NH, et al. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. Int J Radiat Oncol Biol Phys. 2012;83:260–7. This is an early report of the outcomes of a Phase II trial using proton therapy for stage IA-IIIB Hodgkin disease. It describes the dosimetric benefits with protons compared to IMRT or 3DCRT and relates reduction in dose to improved late treatment-related morbidity and mortality. PubMedCrossRefGoogle Scholar
- 31.•Li J, Dabaja B, Reed V, Allen PK, Cai H, Amin MV, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys. 2011;81:167–74. This paper describes ten patients treated using proton therapy for lymphoma (most with Hodgkin lymphoma) and compares the doses to critical structures with proton therapy versus 3DCRT. PubMedCrossRefGoogle Scholar
- 32.•Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschold P, Petersen PM, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24:2113–8. This paper compares treatment plans using involved-node radiotherapy for 27 patients planned with 3DCRT, VMAT, IMPT, or a mantle field. Estimates are made for the risk of cardiovascular morbidity and mortality, secondary lung and breast cancers, and life years lost as a result of treatment toxicity for each treatment modality. PubMedCrossRefGoogle Scholar
- 35.Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck Af Rosenschold P, Petersen PM, et al. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy. Radiother Oncol. 2013.Google Scholar
- 37.Venkatramani R, Kamath S, Wong K, Olch AJ, Malvar J, Sposto R, Goodarzian F, Freyer DR, Keens TG, Mascarenhas L. Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. Pediatr Blood Cancer. 2014.Google Scholar
- 46.Andolino DL, Hoene T, Xiao L, Buchsbaum J, Chang AL. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys. 2011;81:e667–71.PubMedCrossRefGoogle Scholar